XML Print


Chief Researcher, Head of the Laboratory of Natural Focal Infections of the FGBNU “Research Institute of Epidemiology and Microbiology named after G.P. Somova "
Abstract:   (90 Views)
Introduction: The tick-borne encephalitis (TBE) virus causes a dangerous neuroinfection in humans can serve as a model for studying the mechanisms of interaction of pathogens with specific antibodies during active and passive immunization. Several commercial vaccines are currently used against TBE. This review analyzes long-term studies aimed at explaining the active and passive efficacy of specific immunoprophylaxis against TBE. Methods: The effectiveness of "Encepur® adult" TBE vaccine has been studied in terms of seroconversion and strength of the immune response by serological reactions, namely IFA, ELISA and neutralizing were reviewed. Results: Rapid elimination of the virus (after 1-2 days) can occur in vaccinated individuals with antibodies in titers of more than 1: 400. Persons with antibodies in titers of 1: 100 and 1: 200, most likely, should be offered mandatory revaccination. It should also take into account the duration of the retention of post-vaccination antibodies. Conclusion: In the year of TBE vaccination, the immune response was at a high level and practically did not differ. A particularly high level of immune protection was observed in persons who were vaccinated by a combination of TBE vaccines of various producers.
Full-Text [PDF 304 kb]   (35 Downloads)    
Type of Study: Review article | Subject: Prophylactic and therapeutic, and plant-based vaccines
Received: 2021/08/15 | Accepted: 2021/06/10 | Published: 2021/12/15

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.